Considering Options for Advancing to Injectable Therapy in Patients with Type 2 Diabetes (T2D) Uncontrolled on Oral Antihyperglycemic Medications (OAMs)

Despite increasing awareness and new developments in the treatment and prevention of diabetes, there has been a rapid increase in the number of people with T2D.² Tight glycemic control may reduce the risk of diabetes complications in people with T2D.³ Non-adherence to treatment is a barrier to effective care. Only Read more…

The Efficacy of the GLP-1 Receptor Agonist Drugs, Dulaglutide and Liraglutide, for Control of Hyperglycemia in Type 2 Diabetes (T2D)

Despite increasing awareness and new developments in the treatment and prevention of diabetes, there has been a rapid increase in the number of people with T2D.²Tight glycemic control may reduce the risk of diabetes complications in people with T2D.³ Non-adherence to treatment is a barrier to effective care. Only 50% Read more…

Addressing Hyperglycemia in Type 2 Diabetes (T2D) Patients with Moderate-to-Severe Chronic Kidney Disease

Once-weekly dulaglutide compared with daily insulin glargine as basal therapy, both in combination with insulin lispro1 Despite increasing awareness and new developments in the treatment and prevention of diabetes, there has been a rapid increase in the number of people with T2D.² Tight glycemic control may reduce the risk of Read more…

The PARADIGM study

Premixed insulin (75% insulin lispro protamine suspension,  25% insulin lispro) is non-inferior to glargine+lispro. The PARADIGM study  Patients with type 2 diabetes (T2D) can fail to achieve optimal glycaemic control despite  diet, exercise and oral anti-hyperglycaemic agents, however, long-term glycaemic control  on insulin therapy reduces the risk of both micro and Read more…